Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Michael Catelani Acquires 9,289 Shares

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) CFO Michael Catelani acquired 9,289 shares of the stock in a transaction dated Wednesday, January 15th. The shares were acquired at an average cost of $2.15 per share, with a total value of $19,971.35. Following the completion of the transaction, the chief financial officer now owns 44,500 shares in the company, valued at approximately $95,675. This represents a 26.38 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Anixa Biosciences Trading Up 7.0 %

Shares of NASDAQ ANIX traded up $0.15 during trading hours on Wednesday, reaching $2.28. The stock had a trading volume of 304,271 shares, compared to its average volume of 100,660. The firm has a market cap of $73.37 million, a price-to-earnings ratio of -5.85 and a beta of 0.82. Anixa Biosciences, Inc. has a fifty-two week low of $2.07 and a fifty-two week high of $5.13. The firm has a 50-day moving average of $2.86 and a 200-day moving average of $3.03.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last announced its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. On average, equities analysts predict that Anixa Biosciences, Inc. will post -0.42 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, November 19th. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Anixa Biosciences in a research report on Tuesday.

Institutional Trading of Anixa Biosciences

Large investors have recently made changes to their positions in the company. Concorde Asset Management LLC purchased a new stake in Anixa Biosciences during the 2nd quarter valued at approximately $31,000. Virtu Financial LLC purchased a new stake in Anixa Biosciences during the 3rd quarter valued at approximately $34,000. Westside Investment Management Inc. raised its stake in Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company's stock valued at $110,000 after acquiring an additional 21,100 shares during the last quarter. Tyler Stone Wealth Management raised its stake in Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company's stock valued at $132,000 after acquiring an additional 21,008 shares during the last quarter. Finally, International Assets Investment Management LLC raised its stake in Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company's stock valued at $1,190,000 after acquiring an additional 23,800 shares during the last quarter. 29.13% of the stock is owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.